High betatrophin in coronary patients protects from cardiovascular events.

Leiherer A; Ebner J; Muendlein A; Brandtner EM; Zach C; Geiger K; Fraunberger P; Drexel H

doi:10.1016/j.atherosclerosis.2019.11.011

Back

Journal article

High betatrophin in coronary patients protects from cardiovascular events.

Leiherer A Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Medical Central Laboratories, Feldkirch, Austria. Electronic address: andreas.leiherer@vivit.at.
Ebner J Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria.
Muendlein A Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein.
Brandtner EM Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Zach C Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria.
Geiger K Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Fraunberger P Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Medical Central Laboratories, Feldkirch, Austria.
Drexel H Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Drexel University College of Medicine, Philadelphia, PA, USA; Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Switzerland.

2019-12-22

Published in:

Atherosclerosis. - 2020

English BACKGROUND AND AIMS
Betatrophin, also known as angiopoietin-like protein 8 (ANGPTL8) or lipasin, is a nutritionally-regulated mammalian-specific protein secreted by the liver and adipose tissue. Many conflicting data exist with respect to its association with type 2 diabetes mellitus (T2DM), insulin resistance, and lipid markers, but no data are available on its association with cardiovascular risk.

METHODS
We measured betatrophin in 553 coronary patients undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD) and prospectively recorded cardiovascular events during a follow-up of up to 8 years.

RESULTS
During follow-up, 201 patients suffered a cardiovascular event and 64 died from cardiovascular causes. High betatrophin (upper tertile) was significantly and inversely associated with cardiovascular events both univariately (HR = 0.64 [95%CI 0.47-0.87], p = 0.004) and after full adjustment including the status of CAD and T2DM (adj. HR = 0.55 [95%CI 0.40-0.76], p < 0.001). The inclusion of betatrophin into a basic prediction model for the cardiovascular event risk significantly improved the model performance (NRI = 0.728, p < 0.001).

CONCLUSIONS
This study is the first to show that betatrophin predicts cardiovascular events independently of conventional risk factors including the presence of CAD and T2DM.

Language